December 20, 2013
Stories this photo appears in:
Cardium Therapeutics Inc. has entered a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co. Ltd. of China to support the worldwide clinical and commercial development of San Diego-based Cardium’s regenerative medicine therapeutics products.
Cardium Therapeutics Inc. announced that it elected to delist from the New York Stock Exchange and voluntarily begin trading on the OTC exchange.
Cardium Therapeutics Inc., which could face possible suspension or removal from the New York Stock Exchange, has until Jan. 6, 2014 to submit an updated plan of compliance to the exchange.